首页/数据集/Summary of post-baseline laboratory abnormalities.

Summary of post-baseline laboratory abnormalities.

Figshare2019-01-02 更新2026-04-29 收录

临床实验室异常监测

药物安全性评估

数据链接：

https://figshare.com/articles/dataset/Summary_of_post-baseline_laboratory_abnormalities_/7540022 数据链接链接失效反馈

官方服务：

资源简介：

Summary of post-baseline laboratory abnormalities.

应用场景：

创建时间：

2019-01-02

药物不良反应监测

药物安全性评估

This study analyzed adverse drug event (ADE) signals associated with metreleptin using the FDA Adverse Event Reporting System (FAERS) to provide insights for safe clinical use. Data from 1 January 201

DataCite Commons2026-05-04 更新60

Subgroup analysis of the association between PPI therapy and significant small-bowel lesions in users and non-users of nonsteroidal anti-inflammatory drugs.

药物安全性评估

胃肠道病变关联分析

Subgroup analysis of the association between PPI therapy and significant small-bowel lesions in users and non-users of nonsteroidal anti-inflammatory drugs.

NIAID Data Ecosystem40

Results of univariate logistic regressions in cases treated with GLD dead due to confirmed fatal hyperglycaemia versus matched controls.

药物安全性评估

高血糖症风险分析

Categorical variables given as number and proportions (%).

NIAID Data Ecosystem40

Megadoses and mortality (multivariate analysis adjusted according to patient age, comorbidities and other treatments).

药物安全性评估

临床流行病学

Megadoses and mortality (multivariate analysis adjusted according to patient age, comorbidities and other treatments).

NIAID Data Ecosystem50

Adverse events by treatment arm, intention-to-treat population (N = 1761).